1.83

3.17% -0.06

Brainstorm Cell Therapeutics Inc (BCLI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCLI Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.89

Aprire:

$1.873

Volume 24 ore:

12,121

Relative Volume:

0.12

Capitalizzazione di mercato:

$10.44M

Reddito:

Utile/perdita netta:

$-16.63M

Rapporto P/E:

-4.2558

EPS:

-0.43

Flusso di cassa netto:

$-21.84M

1 W Prestazione:

-4.19%

1M Prestazione:

-20.09%

6M Prestazione:

-57.52%

1 anno Prestazione:

-68.64%

Intervallo 1D:

$1.81

$1.918

Intervallo di 1 settimana:

$1.71

$1.9594

Portata 52W:

$1.05

$11.89

Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile

Nome

Brainstorm Cell Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (679)

Telefono

201-488-0460

Indirizzo

1325 AVENUE OF AMERICAS, NEW YORK, NY

Dipendente

Cinguettio

@BrainStormCell

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

BCLI's Discussions on Twitter

Confronta BCLI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCLI Brainstorm Cell Therapeutics Inc	1.83	10.44M	0	-16.63M	-21.84M	-0.43
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-02-04	Aggiornamento	Maxim Group	Hold → Buy
2020-11-17	Downgrade	Maxim Group	Buy → Hold
2016-12-19	Reiterato	Maxim Group	Buy
2015-12-22	Reiterato	Maxim Group	Buy

Brainstorm Cell Therapeutics Inc Borsa (BCLI) Ultime notizie

Feb 01, 2025

5 Best Stem Cell Companies to Invest In (February 2025) - Securities.io

Feb 01, 2025

Jan 30, 2025

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire

Jan 30, 2025

Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, - openPR

Jan 30, 2025

Jan 29, 2025

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World

Jan 29, 2025

Jan 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire

Jan 27, 2025

Jan 23, 2025

Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN

Jan 23, 2025

Jan 21, 2025

Brainstorm Cell Therapeutics Appeals Nasdaq Delisting By Investing.com - Investing.com Australia

Jan 21, 2025

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com - Defense World

Jan 21, 2025

Jan 15, 2025

Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail

Jan 15, 2025

Brainstorm Cell Therapeutics faces Nasdaq delisting By Investing.com - Investing.com Nigeria

Jan 15, 2025

Brainstorm Cell Therapeutics faces Nasdaq delisting - Investing.com

Jan 15, 2025

Jan 12, 2025

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - GuruFocus.com

Jan 12, 2025

Jan 10, 2025

StockNews.com Downgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Sell - Defense World

Jan 10, 2025

Jan 09, 2025

Mesenchymal Stem Cells Market Outlook 2024: Emerging Trends and Regulatory Shifts Shaping the Future - WICZ

Jan 09, 2025

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - GuruFocus.com

Jan 03, 2025

Dec 30, 2024

BrainStorm Cell Therapeutics Announces Key Milestones and Strategic Plans for ALS Therapy NurOwn® - Tandav Media

Dec 30, 2024

BrainStorm Cell Advances NurOwn ALS Treatment with FDA Special Protocol Assessment and Manufacturing Deal - StockTitan

Dec 30, 2024

BrainStorm Issues 2024 Letter to Shareholders - PR Newswire

Dec 30, 2024

Dec 12, 2024

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online

Dec 12, 2024

Dec 11, 2024

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online

Dec 11, 2024

Dec 10, 2024

Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR

Dec 10, 2024

Dec 07, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald

Dec 07, 2024

Dec 06, 2024

Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR

Dec 06, 2024

Dec 04, 2024

BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria

Dec 04, 2024

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard

Dec 04, 2024

Dec 03, 2024

BrainStorm secures patent for exosome technology - Investing.com

Dec 03, 2024

Dec 01, 2024

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Marketscreener.com

Dec 01, 2024

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR

Nov 29, 2024

Nov 22, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Mini - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024

Nov 18, 2024

Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR

Nov 18, 2024

Nov 15, 2024